Genomic insights into the evolution and mechanisms of carbapenem-resistant hypervirulent Klebsiella pneumoniae co-harboring blaKPC and blaNDM: implications for public health threat mitigation

Wang, Qian; Liu, Yue; Chen, Ran; Zhang, Meng; Si, Zaifeng; Wang, Yueling; Jin, Yan; Bai, Yuanyuan; Song, Zhen; Lu, Xinglun; Hao, Mingju; Hao, Yingying

doi:10.1186/s12941-024-00686-3

Annals of Clinical Microbiology and Antimicrobials

Table 2 Microbiological characteristics of clinical isolated

From: Genomic insights into the evolution and mechanisms of carbapenem-resistant hypervirulent Klebsiella pneumoniae co-harboring bla_KPC and bla_NDM: implications for public health threat mitigation

Isolate	Carbapenemase	MLST	MIC (μg/mL)
Isolate	Carbapenemase	MLST	TZP	CAZ	CRO	FEP	ATM	ETP	IPM	AMK	GEN	CIP	LVX	SXT	POL	TGC
JNKPN01	KPC-2	ST11	≥ 128	≥ 64	≥ 64	≥ 64	≥ 64	≥ 32	≥ 16	≥ 64	≥ 16	≥ 4	≥ 8	≤ 1	1	0.5
JNKPN03	KPC-2	ST11	≥ 128	≥ 64	≥ 64	≥ 64	≥ 64	≥ 32	≥ 16	≥ 64	≥ 16	≥ 4	≥ 8	≤ 1	0.5	2
JNKPN05	KPC-2	ST11	≥ 128	≥ 64	≥ 64	≥ 64	≥ 64	≥ 32	≥ 16	≤ 2	≥ 16	≥ 4	≥ 8	≤ 1	1	1
JNKPN15	KPC-2	ST11	≥ 128	≥ 64	≥ 64	≥ 64	≥ 64	≥ 32	≥ 16	≥ 64	≥ 16	≥ 4	≥ 8	≤ 1	1	0.5
JNKPN23	KPC-2; NDM-1	ST11	≥ 128	≥ 64	≥ 64	≥ 64	≥ 64	≥ 32	≥ 16	≥ 64	≥ 16	≥ 4	≥ 8	≥ 16	1	0.5
JNKPN24	KPC-2; NDM-1	ST11	≥ 128	≥ 64	≥ 64	≥ 64	≥ 64	≥ 32	≥ 16	≥ 64	≥ 16	≥ 4	≥ 8	≥ 16	0.5	1
JNKPN26	KPC-2; NDM-1	ST11	≥ 128	≥ 64	≥ 64	≥ 64	≥ 64	≥ 32	≥ 16	≥ 64	≥ 16	≥ 4	≥ 8	≥ 16	> 64	1
JNKPN28	KPC-2	ST11	≥ 128	≥ 64	≥ 64	≥ 64	≥ 64	≥ 32	≥ 16	≥ 64	≥ 16	≥ 4	≥ 8	≤ 1	0.5	0.5
JNKPN29	KPC-2; NDM-1	ST11	≥ 128	≥ 64	≥ 64	≥ 64	≥ 64	≥ 32	≥ 16	≥ 64	≥ 16	≥ 4	≥ 8	≥ 16	0.5	1
JNKPN30	NDM-1	ST11	≥ 128	≥ 64	≥ 64	≥ 64	≥ 64	≥ 32	≥ 16	≥ 64	≥ 16	≥ 4	≥ 8	≥ 16	0.5	2
JNKPN31	KPC-2; NDM-1	ST11	≥ 128	≥ 64	≥ 64	≥ 64	≥ 64	≥ 32	≥ 16	≥ 64	≥ 16	≥ 4	≥ 8	≥ 16	1	1
JNKPN34	KPC-2	ST11	≥ 128	≥ 64	≥ 64	≥ 64	≥ 64	≥ 32	≥ 16	≥ 64	≥ 16	≥ 4	≥ 8	≤ 1	1	1
JNKPN37	KPC-2	ST11	≥ 128	≥ 64	≥ 64	≥ 64	≥ 64	≥ 32	≥ 16	≥ 64	≥ 16	≥ 4	≥ 8	≤ 1	1	2
JNKPN38	KPC-2	ST11	≥ 128	≥ 64	≥ 64	≥ 64	≥ 64	≥ 32	≥ 16	≥ 64	≥ 16	≥ 4	≥ 8	≤ 1	0.5	0.75
JNKPN49	KPC-2	ST11	≥ 128	≥ 64	≥ 64	≥ 64	≥ 64	≥ 32	≥ 16	≥ 64	≥ 16	≥ 4	≥ 8	≥ 16	0.5	0.25
JNKPN58	KPC-2	ST11	≥ 128	≥ 64	≥ 64	≥ 64	≥ 64	≥ 32	≥ 16	≤ 2	≤ 1	≥ 4	≥ 8	≤ 1	0.5	1

MIC minimal inhibitory concentrations, CRO ceftriaxone, FEP cefepime, CAZ ceftazidime, ATM aztreonam, TZP piperacillin–tazobactam, ETP ertapenem, IMP imipenem, SXT trimethoprim–sulfamethoxazole, AMK amikacin, GEN gentamicin, CIP ciprofloxacin, LVX levofloxacin, TGC tigecycline, POL polymyxin

Back to article page

ISSN: 1476-0711

Contact us

Submission enquiries: journalsubmissions@springernature.com